rss
Arch Dis Child 2007;92:759-766 doi:10.1136/adc.2006.104752
  • Original article

Vitamin K deficiency bleeding in Great Britain and Ireland: British Paediatric Surveillance Unit Surveys, 1993–94 and 2001–02

  1. Andrew McNinch1,
  2. Alison Busfield1,
  3. John Tripp2
  1. 1
    Royal Devon and Exeter NHSF Trust, Barrack Road, Exeter, UK
  2. 2
    Peninsula Medical School, Exeter, UK
  1. Andrew McNinch, Royal Devon and Exeter NHSF Trust, Barrack Road, Exeter EX2 5DW, UK; awmcninch{at}doctors.org.uk
  • Accepted 9 May 2007
  • Published Online First 30 May 2007

Abstract

Objective: To conduct and report monitoring of vitamin K deficiency bleeding (VKDB) in Great Britain and Ireland following the 1988–90 survey (VKDB-90).

Design: Two 2-year surveys conducted during 1993–4 (VKDB-94) and 2001–02 (VKDB-02).

Setting: Data collected from all consultant paediatricians in Great Britain and Ireland.

Patients: All infants presenting with bleeding resulting from vitamin K (VK) deficiency.

Main outcome measures: Incidence of VKDB, related mortality/morbidity and VK prophylaxis recommended/received, noting predisposing features.

Results: Compared with previous studies, VKDB-02 found fewer cases of VKDB (RR: 0.27 (95% CI: 0.12 to 0.59), p<0.001) with no deaths, no long-term morbidity and reduced incidence among those receiving any oral dosing (RR: 0.24 (95% CI: 0.06 to 1.01), p<0.059). Breast-fed infants accounted for the vast majority of cases. The number receiving no prophylaxis fell consecutively over time: 20 of 27 in VKDB-90, 10 of 32 in VKDB-94 and 4 (because of parental refusal) of 7 in VKDB-02. Seven received one oral dose of VK in VKDB-90, 16 in VKDB-94 and none in VKDB-02. Underlying liver disease was found in six cases in VKDB-90, 12 in VKDB-94 and one in VKDB-02.

Conclusions: In the most recent survey, the incidence of VKDB was about one third that in the two earlier studies. Late onset VKDB remains virtually confined to breast-fed infants who have received either no VK or just one oral dose. The effectiveness of oral prophylaxis regimens has improved over the last 15 years, but parental refusal of prophylaxis has become more problematic.

Footnotes

  • Competing interests: JHT and AWM have previously received funding from Roche Pharmaceuticals. JHT has acted as an expert witness to the MHCA in an appeal for approval of an oral preparation of vitamin K1 by another company.

  • Abbreviations:
    BPSU
    British Paediatric Surveillance Unit
    ICH
    intracranial haemorrhage
    IM
    intramuscular
    VK
    vitamin K
    VKDB
    vitamin K deficiency bleeding

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

ADC is co-owned by the RCPCH and is the official journal of the European Academy of Paediatrics